Related Experiment Video
Updated: May 17, 2026
07:25
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Landmarks in hormonal therapy for prostate cancer
Peter Hammerer1, Stephan Madersbacher
1Department of Urology, Academic Hospital Braunschweig, Vienna, Austria. p.hammerer@klinikumbraunschweig.de
BJU International
|October 11, 2012
Summary
Androgen-deprivation therapy (ADT) is standard for advanced prostate cancer, with luteinizing hormone-releasing hormone (LHRH) agonists widely used. New agents are needed as castration-resistant disease is inevitable.
Area of Science:
- Oncology
- Urology
- Endocrinology
Background:
- Prostate cancer is the most common cancer in men.
- Androgen deprivation therapy (ADT) has been the standard of care for over 70 years.
- Luteinizing hormone-releasing hormone (LHRH) agonists are the primary form of ADT due to extensive evidence.
Purpose of the Study:
- To review the evolution and current status of ADT in prostate cancer management.
- To highlight the importance of personalized treatment strategies.
- To emphasize the ongoing need for novel therapeutic agents.
Main Methods:
- Review of historical data and clinical trial evidence.
- Analysis of treatment guidelines and therapeutic progress.
- Discussion of current ADT modalities and future directions.
Main Results:
- ADT remains the cornerstone for non-localized prostate cancer.
- LHRH agonists are the established standard of care for ADT.
- Individualized treatment approaches are crucial for optimal outcomes.
Conclusions:
- Despite advances, ADT is essential for prostate cancer treatment.
- The development of castration-resistant prostate cancer necessitates new therapeutic agents.
- Continued research into novel ADT agents is critical for improving patient survival and quality of life.
Related Concept Videos
01:20Disorders of the Male Reproductive System
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...